Trodelvy has been found to have fewer side effects than chemotherapy in some patients with triple-negative breast cancer. The treatment has shown significant benefits in advanced cases of this cancer type. However, its effectiveness is still being compared to other treatments, with some studies suggesting other options may outperform it in certain areas.